Regeneron Pharmaceuticals traded at $734.99 this Thursday November 17th, decreasing $0.68 or 0.09 percent since the previous trading session. Looking back, over the last four weeks, Regeneron Pharmaceuticals lost 1.70 percent. Over the last 12 months, its price rose by 13.34 percent. Looking ahead, we forecast Regeneron Pharmaceuticals to be priced at 710.29 by the end of this quarter and at 642.46 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
735.48
Daily Change
-0.03%
Yearly
13.41%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Kyowa Hakko Kirin 3,165.00 55.00 1.77% -6.77%
Astellas Pharma 2,067.50 7.00 0.34% 6.46%
AbbVie 151.88 0.01 0.01% 29.73%
Agenus 3.23 -0.03 -0.77% -8.64%
Agios Pharmaceuticals 27.48 0.35 1.29% -30.73%
Alimera Sciences 4.30 0.05 1.18% -22.52%
Alnylam Pharmaceuticals 208.60 -3.39 -1.60% 16.55%
Amgen 287.58 3.81 1.34% 40.96%
AstraZeneca 10,788.00 40.00 0.37% 28.72%
Biogen 299.93 -0.08 -0.03% 16.80%
Bluebird Bio 6.84 -0.30 -4.20% -37.31%
BioMarin Pharmaceutical 86.91 1.07 1.25% 4.81%
Bristol-Myers Squibb 77.27 1.12 1.47% 30.88%
Esperion Therapeutics 7.18 -0.13 -1.71% -6.33%
Gilead Sciences 83.49 0.61 0.74% 23.16%
GlaxoSmithKline 1,352.20 -22.20 -1.62% -10.57%
Intercept Pharmaceuticals 14.82 -0.27 -1.79% -15.27%
Incyte Corp 77.95 1.24 1.62% 19.68%
Ionis Pharmaceuticals 42.76 0.07 0.16% 33.04%
J&J 174.19 0.73 0.42% 7.26%
Eli Lilly 359.77 6.84 1.94% 37.67%
Merck & Co 102.24 2.31 2.31% 23.11%
Moderna Inc 183.18 -2.07 -1.12% -27.14%
Neurocrine Biosciences 114.67 2.00 1.78% 31.04%
Novartis 79.04 0 0% 4.34%
Novartis 82.74 -0.82 -0.98% 0.93%
Iveric bio Inc. 16.87 -0.48 -2.77% 4.20%
Opthea Ltd 0.99 -0.01 -1.01% -20.56%
Puma Biotechnology 3.54 0.40 12.74% 5.04%
Pfizer 48.06 0.01 0.02% -6.52%
Ultragenyx Pharmaceutical 34.39 -0.83 -2.36% -55.56%
Regeneron Pharmaceuticals 735.48 -0.19 -0.03% 13.41%
Roche Holding 307.45 -4.70 -1.51% -16.60%
Seattle Genetics 131.23 -0.33 -0.25% -28.76%
Sanofi 43.48 -0.38 -0.86% -13.33%
Sarepta Therapeutics 109.51 0.24 0.22% 35.35%
Teva Pharmaceutical Industries Ltd 3,020.00 -112.00 -3.58% 8.91%
United Therapeutics 257.90 -3.15 -1.21% 27.29%
Vertex Pharmaceuticals 310.25 4.81 1.57% 67.33%

Indexes Price Day Year
US500 3937 -22.46 -0.57% -16.32%
USND 11083 -100.19 -0.90% -30.70%
USNDX 11671 -28.48 -0.24% -29.20%

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.